Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
87 hedge funds and large institutions have $117M invested in Enzo Biochem, Inc. in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 26 increasing their positions, 33 reducing their positions, and 13 closing their positions.
7% more capital invested
Capital invested by funds: $109M → $117M (+$8.02M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 95 → 87 (-8)
21% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 33
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
+$2.49M |
| 2 |
HFA
Harbert Fund Advisors
Birmingham,
Alabama
|
+$1.6M |
| 3 |
EGA
Evermore Global Advisors
Summit,
New Jersey
|
+$1.49M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$658K |
| 5 |
FM
Fondren Management
Houston,
Texas
|
+$634K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$4.17M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.01M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$432K |
| 4 |
D.E. Shaw & Co
New York
|
-$344K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$328K |
ENZ Hedge Fund Activity: Q3 2019 in Review
87 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2019, worth a combined $117M — up 7.3% from $109M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ENZ and 5 opened new positions — a net loss of 8 holders — while 33 trimmed existing stakes and 26 added.
The largest buyer was Ariel Investments, adding an estimated $2.49M. The largest seller was Roumell Asset Management, exiting entirely with an estimated $4.17M sold.
- 87 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2019, down from 95 in Q2 2019.
- Funds reported $117M of Enzo Biochem, Inc. stock for Q3 2019, up 7.3% quarter-over-quarter.
- 5 funds opened new Enzo Biochem, Inc. positions in Q3 2019 and 13 closed out, a net change of -8 holders.
- The largest Enzo Biochem, Inc. buyer in Q3 2019 was Ariel Investments, an estimated $2.49M added.
- The largest Enzo Biochem, Inc. seller in Q3 2019 was Roumell Asset Management, an estimated $4.17M sold.
Based on aggregated 13F filings for Q3 2019.